298. Hereditary pancreatitis Clinical trials / Disease details

Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-000732-34-DK (EUCTR)	21/06/2017	25/04/2017	Drug Release and Absorption from Controlled Release Formulations in Patients with Gastrointestinal Dysfunctions.	Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? - ABOXY	Healthy (pain) and patients (pain). MedDRA version: 20.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis;System Organ Class: 100000004856 MedDRA version: 20.0;Classification code 10012594;Term: Diabetes;System Organ Class: 100000004861 MedDRA version: 20.0;Classification code 10048516;Term: Gastrointestinal disorder (NOS);Classification code 10050554;Term: Gastric bypass NOS;System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Oxynorm Product Name: Oxynorm INN or Proposed INN: Oxycodone Other descriptive name: OXYCODONE Trade Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets Product Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets INN or Proposed INN: Oxycodone Other descriptive name: OXYCODONE HYDROCHLORIDE Trade Name: Oxycodone Depot ”Sandoz”, depot tablets Product Name: Oxycodone Depot ”Sandoz”, depot tablets INN or Proposed INN: Oxycodone Other descriptive name: OXYCODONE HYDROCHLORIDE	Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University Hospital	NULL	Not Recruiting			Female: yes Male: yes	135	Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Denmark